Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
ID: 358823Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358823

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-383.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)" aimed at supporting innovative research in the development of therapeutic and diagnostic devices for disorders affecting the nervous or neuromuscular systems. This cooperative agreement program encourages investigators to conduct translational activities and clinical feasibility studies, with a focus on advancing medical device technology through collaboration with NIH resources for design, testing, and regulatory support. The initiative is particularly significant as it seeks to accelerate the clinical introduction of medical technologies, ultimately improving patient outcomes while adhering to best practices in research and development. Interested applicants, including various eligible institutions and organizations, must submit their proposals by January 28, 2028, and can find more information at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-383-Full-Announcement.html
    PAR-25-383.html
    The Department of Health and Human Services has issued a Notice of Funding Opportunity (NOFO) through the National Institutes of Health (NIH) to support innovative research in medical device development aimed at preventing, monitoring, diagnosing, and treating disorders associated with various health conditions. The Blueprint MedTech Translator program encourages applications from researchers to advance clinical studies and translational activities related to medical devices while facilitating collaboration with NIH resources for design, testing, and regulatory support. Interest covers devices in diverse fields, leveraging NIH's BRAIN and HEAL Initiatives. The funding mechanism includes two phases: UG3 for initial translational activities and UH3 for subsequent clinical studies, with a total proposed project period not exceeding five years. Applicants must meet entry criteria including significant preliminary data and a compelling plan for device functionality, safety, and regulatory compliance. The application process emphasizes compliance with specific guidelines and requires detailed plans for testing, timelines, and interactions with regulatory bodies. The initiative aims to accelerate the clinical introduction of medical technologies, ultimately improving patient outcomes while ensuring adherence to best practices in research and development.
    Similar Opportunities
    Forecast for Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to release a Notice of Funding Opportunity (NOFO) for the Blueprint MedTech Translator program, aimed at supporting small businesses in the development of innovative medical devices for the nervous and neuromuscular systems. This cooperative agreement will provide non-dilutive funding and additional resources to facilitate the translation of groundbreaking technologies from early-stage development to clinical studies, ultimately accelerating patient access to effective medical devices. Interested applicants should note that while applications are not currently being solicited, they are encouraged to begin forming collaborations and developing projects in anticipation of the NOFO, with an estimated synopsis posting date of July 21, 2025, and a closing date of October 20, 2025. For further inquiries, potential applicants can contact Nicholas Langhals, PhD, at Blueprint-MedTech@nih.gov or by phone at 301-435-0090.
    Translational Neural Devices (R61/R33 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Neural Devices (R61/R33 - Clinical Trial Optional)" aimed at advancing the development of therapeutic and diagnostic devices for neurological and neuromuscular disorders. This initiative encourages investigators to engage in translational activities and small clinical studies, focusing on the implementation of clinical prototype devices, non-clinical safety and efficacy testing, and obtaining necessary regulatory approvals for clinical trials. The program emphasizes a milestone-driven approach, requiring collaboration with NIH staff throughout the project, and aims to address health disparities in neurological health. Interested applicants, including various educational and community organizations, must submit their proposals by January 28, 2027, and can find additional information and application guidelines at NIH Grants.
    Translational Neural Devices (R61/R33 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Translational Neural Devices (R61/R33 - Clinical Trial Optional)" aimed at advancing the development of therapeutic and diagnostic devices for neurological and neuromuscular disorders. This funding opportunity supports projects through two phases: R61 for non-clinical activities and R33 for small clinical studies, with a focus on ensuring compliance with Environmental Health and Safety regulations. The program emphasizes diversity in applicant teams and requires a Plan for Enhancing Diverse Perspectives, with key deadlines including submission openings starting December 28, 2024, and a close date of January 28, 2027. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for clinical studies aimed at advancing next-generation devices for recording and modulation in the human central nervous system, under the BRAIN Initiative. This initiative seeks to support small clinical trials that provide critical data necessary for the development of devices intended to treat central nervous system disorders, particularly those requiring an Investigational Device Exemption (IDE) from the FDA. The funding is crucial for enhancing neurotechnology and improving treatment outcomes, with NIH planning to allocate approximately $10 million annually for 5 to 7 awards, each with a maximum budget of $1.5 million per year for up to five years. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by September 28, 2026.
    Small Business Translator: MedTech and Digital Health Technologies
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Small Business Translator: MedTech and Digital Health Technologies" aimed at encouraging small business concerns (SBCs) to engage in translational activities and clinical studies for the development of innovative health technologies. This cooperative agreement program seeks to advance technologies that prevent, monitor, diagnose, and treat various disorders, with a focus on devices such as wearables, digital health tools, and imaging-based biomarkers, among others. Participants will receive funding for activities conducted in their laboratories and may also collaborate with consultants for specialized support, with key deadlines including an estimated synopsis close date of October 20, 2025, and an estimated award date of July 1, 2026. For further inquiries, interested applicants can contact Nicholas Langhals, PhD, at Blueprint-MedTech@nih.gov or by phone at 301-435-0090.
    Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint MedTech: Prototype Developer (U18 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity announcement for the Blueprint MedTech: Prototype Developer program, aimed at supporting the development of human-grade medical device prototypes. This initiative will utilize the U18 activity code and is designed to assist projects in completing product definition and development, including needs assessment, product design, prototype development, and bench testing, ultimately preparing for first-in-human testing through subsequent FOAs. The program is significant for advancing medical technology and innovation in healthcare, with no cost-sharing or matching requirements. Interested applicants can reach out to Michael Wolfson, Ph.D., at 301-451-6987 or via email at Blueprint-MedTech@nih.gov for further information. The estimated synopsis post date was July 15, 2021, with applications expected to be due in Fall 2021, and the anticipated award date is June 1, 2022.
    BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity under the BRAIN Initiative, aimed at advancing the development of next-generation devices for recording and modulation in the human central nervous system (CNS). This initiative encourages investigators to engage in translational activities and small clinical studies that focus on therapeutic and diagnostic devices for CNS disorders, particularly those requiring an Investigational Device Exemption (IDE) from the FDA. The program is structured in two phases: the UG3 phase for regulatory activities and the UH3 phase for conducting clinical studies, with a total project period not exceeding five years. NIH anticipates allocating approximately $10 million per year to fund 5 to 7 awards, with applications due by September 28, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the BRAIN Initiative to support the development of next-generation devices for recording and modulation in the human central nervous system. This initiative aims to facilitate translational activities and small clinical studies focused on therapeutic and diagnostic devices for CNS disorders, particularly those requiring Investigational Device Exemptions (IDE) for significant risk studies. The program emphasizes milestone-driven cooperative agreements, collaboration among diverse research teams, and the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to promote equitable access in research. With an annual budget of $10 million available for approximately 5 to 7 awards, interested applicants can find more information and apply starting April 29, 2024, by contacting NIH Grants Information at grantsinfo@nih.gov.
    BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the BRAIN Initiative to support clinical studies aimed at advancing next-generation devices for recording and modulation within the human central nervous system (CNS). This initiative encourages proposals for early-stage clinical investigations, including first-in-human studies, that focus on treating CNS disorders and enhancing understanding of brain functions, particularly through Significant Risk studies requiring FDA Investigational Device Exemptions (IDEs) for chronic implants. The NIH plans to allocate approximately $10 million annually to fund 5 to 7 projects, emphasizing the importance of collaborations with device manufacturers through a public-private partnership program, and requires a Plan for Enhancing Diverse Perspectives as part of the application. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with the application deadline set for January 28, 2027.
    Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System," aimed at supporting the development of biologic therapies for nervous and neuromuscular disorders. This initiative is structured as a cooperative agreement, divided into two phases: UG3 for lead optimization and UH3 for IND-enabling activities, with a focus on specific treatment applications for these disorders. The program encourages collaboration with NIH resources, including access to contract research organizations and experienced consultants, to facilitate the development of innovative therapies. Interested applicants, including higher education institutions and nonprofits, are encouraged to apply by August 18, 2027, and can find more information at the provided NIH grants link or contact NIH Grants Information at grantsinfo@nih.gov.